NAMSNewAmsterdam Pharma Company N.V.
$21.58-19% 1Y
$21.58
$21.1452 weeks$41.45
NAMS in its own filings
NAMS's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
127
Events found in the filings · across 412 filings · the record starts in 2022
- Hard flags
- 1
Hard flags
- Most recent filing
- Sep 29, 2026
Most recent filing · Form 8-K
- Record starts
- Aug 31, 2022
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 4, 2026
- Restatement admitted (non-reliance)past_3y
- 2024-10-18
- SEC comment-letter activity21 occurrences
- 2025-03-06
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 29, 2026On September 29, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) announced the dosing of the first patient in SPINOZA, a Phase 2b clinical trial evaluating obicetrapib in individuals with preclinical Alzheimer’s disease.Other event · Form 8-K
- Sep 21, 2026On September 21, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) along with its partner Menarini Group (“Menarini”) announced that the European Commission (“EC”) has granted marketing authorization for Ubeslo ® (obicetrapib 10 mg monotherapy) and Evlarco ® (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose …Other event · Form 8-K
- Aug 14, 2026As previously disclosed on July 22, 2026, Douglas Kling resigned as the Company’s Chief Operating Officer, effective August 14, 2026 (the “Separation Date”), to be appointed as the chief executive officer of another clinical-stage biotech company.Director or officer change · Form 8-K/A
- Aug 14, 2026On August 10, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) appointed Robert W. Gunning, age 55, as its principal accounting officer.Director or officer change · Form 8-K
- Aug 5, 2026NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results.Earnings release · press release
- Jul 24, 2026On July 24, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) issued a press release announcing that the Company and the Menarini Group have received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency recommending marketing authorization for Ubeslo® …Other event · Form 8-K
- Jul 22, 2026On July 16, 2026, Douglas Kling notified NewAmsterdam Pharma Company N.V. (the “Company”) that he would resign as the Company’s Chief Operating Officer, effective August 14, 2026, to be appointed as the chief executive officer of another clinical-stage biotech company.Director or officer change · Form 8-K
- Jun 3, 2026On June 2, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) held its 2026 annual general meeting of shareholders (the “Annual General Meeting”) in Amsterdam, the Netherlands.Director or officer change · Form 8-K
- May 7, 2026NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results.Earnings release · press release
- Apr 24, 2026On April 20, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) and Louise Kooij agreed that her employment as the Company's Chief Accounting Officer would end effective August 31, 2026 (the “Separation Date“)Director or officer change · Form 8-K
- Mar 2, 2026Currently, Treatment of Hyperlipidemia is One-Dimensional LDL-C, low-density lipoprotein cholesterol; LLT, lipid lower therapy LDL-C ↓ Traditional LLTs.Regulation FD disclosure · press release
- Feb 18, 2026NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…